Senseonics Holdings, Inc. Announces Proposed Public Offering of Common Stock
August 17 2017 - 4:05PM
Business Wire
Senseonics Holdings, Inc. (NYSE MKT: SENS), a medical technology
company focused on the development and commercialization of
Eversense®, a long-term, implantable continuous glucose monitoring
(CGM) system for people with diabetes, today announced that it is
proposing to offer and sell, subject to market conditions, shares
of its common stock in an underwritten public offering. Senseonics
expects to grant the underwriter a 30-day option to purchase up to
an additional 15 percent of the shares of common stock offered in
the public offering to cover over-allotments, if any. Senseonics
intends to use the net proceeds from the offering primarily to
begin commercialization of Eversense in the United States, if
approved, to fund continued research and development of future
configurations of Eversense, and for working capital and general
corporate purposes. The final terms of the offering will depend on
market and other conditions at the time of pricing, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
National Securities Corporation, a wholly owned subsidiary of
National Holdings Corporation (NasdaqCM: NHLD), is acting as sole
book-running manager for the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (“SEC”) on April 3, 2017 and
declared effective by the SEC on April 17, 2017. The offering will
be made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and accompanying prospectus, when
available, may be obtained by contacting the book-running manager
at the following address:
National Securities Corporation200 Vesey St, 25th FloorNew York,
NY 10281Attn: Marguerite RogersTelephone:
(212)-417-8227Email: prospectusrequest@nationalsecurities.com
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Senseonics
Holdings, Inc., and shall not constitute an offer, solicitation or
sale of any security in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of glucose
monitoring products designed to help people with diabetes
confidently live their lives with ease. Senseonics’ first
generation continuous glucose monitoring (CGM) system, Eversense®,
includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to
be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile
device. After insertion, the sensor is designed to continually and
accurately measure glucose levels.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements about the
anticipated public offering, the anticipated use of proceeds and
other statements containing the words “expect,” “intend,” “may,”
“will,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties related to market
conditions and the completion of the underwritten offering on the
anticipated terms or at all, uncertainties inherent in the expanded
commercial launch of Eversense and such other factors as are set
forth in the risk factors detailed in Senseonics’ Annual Report on
Form 10-K for the year ended December 31, 2016, Senseonics’
Quarterly Report on Form 10-Q for the quarter ended June 30, 2017
and Senseonics’ other filings with the SEC under the heading “Risk
Factors.” In addition, the forward-looking statements included in
this press release represent Senseonics’ views as of the date
hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics’ views to change. However, while
Senseonics may elect to update these forward-looking statements at
some point in the future, Senseonics specifically disclaims any
obligation to do so except as required by law. These
forward-looking statements should not be relied upon as
representing Senseonics’ views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170817005917/en/
Senseonics Holdings, Inc.R. Don Elsey, Chief Financial
Officer301-556-1602
Senseonics (AMEX:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024